OVERVIEW

Tobacco Dependence Pharmacotherapy is organized by Duke Cancer Institute (DCI) and will be held on Dec 05, 2023. This course has been approved for 8.0 CME hours.

Description
Medication strategies for tobacco use continue to evolve, with the use of pre-quit treatment, extended treatment, low-dose varenicline, high-dose nicotine, and combination treatment. Most medical providers are unaware of how or when to use these effective approaches.

This training is designed for physicians, physician assistants, nurse practitioners, pharmacists, and tobacco treatment specialists who work with smoking cessation medications and would benefit from an understanding of the current research guiding smoking cessation pharmacotherapy. The course will provide an overview of the neurobiology that gives rise to nicotine dependence and how various medications impact that neurobiology. We will provide guidance on treatment that is relevant to most clinicians including:

approaches to varenicline use that maximize efficacy and minimize side effects;
use of combination medication treatment
evidence for the use of pre-quit smoking cessation medications
use of extended post-quit medications
and the use of adaptive treatment

We explore specific cases, such as the use of tobacco treatment medications in hospitalized patients, surgical patients, acute cardiac care, renal failure, cancer treatment, e-cigarette use, oral tobacco use, and adolescent treatment, as well as treatment of light-intermittent smokers and high-dependence smokers. The course is designed to provide practical guidance for clinicians and lead to real change in clinical practice.